Skip to main content

Essentials of an Effective SOP

BayBiotech.NET

Standard Operating Procedures (SOP) are valuable tool that go beyond the basic procedural description of materials and methods and provide details about the appropriate precautions. A well written SOP is always a binding document in a regulatory environment and defines the details of the procedure to be followed across the board within an organization to perform a specific procedure.

A well written SOP for a particular procedure should evolve with time after repeating the process under Research and Development Unit by testing the feasibility of the steps that makes it an easy to follow methods and minimizes the risks for Out of Specification reporting later on. A well evolved SOP has its origin from a simple stepwise flow chart of a complete process. If any changes are made in the process the SOP version in use must be updated by approval of the appropriate authorities and must be brought in use and supersede any other previous versions.

A typical SOP contains the following elements:

A Header which shows the Title of the SOP, Original Issue Date, Revision/Review Date, number of pages contained in the SOP, who wrote the SOP, and the Approval Signature.

• purpose and scope
• definitions
• materials and equipment needed
• safety concerns,
• who is responsible
• step-by step procedure with identification and emphasis of "critical steps"
• records to be kept
• copies of forms to be used
• References.
SOPs should be reviewed annually at a minimum.

“A well written SOP must have some room for flexibility and ensure that the procedure is compliant with the laws and regulations that you have to support for the purpose of your work.”

References: 1.SOPs: A must for sites, Appl Clin Trials, March 2010.
2. The SOP, http://www.hawaii.edu/ehso/bio/theSOP.htm

Comments

Post a Comment

Popular posts from this blog

Good Machine Learning Practices

BayBiotech.NET A joint effort by FDA,  United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada have developed guiding principles to help promote utilization of medical devices that are safe and effective and utilize artiificial intelligence and machine learning. To find out more details check out the link here!
Post a Comment
Read more

Group C (Treatment IND) Drugs

BayBiotech.NET Since 1976, National Cancer Institute (NCI) in agreement with FDA has established the Group C classification system to allow access to certain drugs for the cancer patients specifically falling under a category that adequate alternative therapy or if the available alternative therapy has significant toxic effects. Each Group C drug protocol specifies patient eligibility and drug use information. Group C drugs are provided only to properly trained physicians who have registered themselves with NCI using a special form to assure that their patient qualifies under guidelines - or protocols - for the drug. Physicians using drugs under Group C have no reporting requirements to the NCI other than the obligation to report adverse drug reactions. Group C drugs are provided free of charge, and the Centers for Medicare and Medicaid Services provides coverage for care associated with Group C therapy. Making Group C drugs available to the critically ill patients not only provi...
Post a Comment
Read more

Amendments for High Risk Device Type Regulatory Pathway

BayBiotech.NET Government Accounting Office (“GAO”) has issued a long-awaited report evaluating the use of the 510(k) process by the Food and Drug Administration (“FDA” or the “Agency”) in the January of 2009. Report mainly focused on Preamendment class III devices. Although most high-risk class III medical devices are subject to the demanding premarket approval (“PMA”) process, preamendment class III devices may be cleared through the 510(k) pathway until FDA issues regulations requiring a PMA. Under the Safe Medical Devices Act of 1990, FDA was required either to reclassify preamendment class III devices into class I or II, or (2) issue regulations requiring PMA approval for the devices, GAO noted that 20 preamendment class III device types have not yet been addressed by the Agency. GAO has urged FDA to take required steps to address the remaining class III devices that continue to be eligible for 510(k) review. As a result of the report, FDA has committed to address al...
Post a Comment
Read more